Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2022 - 03 - 01 save search
Mercury Systems to present at the J.P. Morgan Industrials Conference
Published: 2022-03-01 (Crawled : 23:00) - globenewswire.com
MRCY | $27.46 -0.36% -0.36% 340K
|
Electronic Technology
|
| O: 0.05%
H: 7.71%
C: 2.03%
als trials trial conference system
Northrop Grumman to Participate in J.P. Morgan Industrials Conference
Published: 2022-03-01 (Crawled : 23:00) - globenewswire.com
NOC | $452.05 0.38% -0.34% 750K
|
Electronic Technology
|
| O: 0.5%
H: 2.87%
C: 2.65%
als trials trial conference
CNH Industrial N.V. files 2021 Annual Report on Form 20-F and publishes 2021 EU Annual Report; calling of the Annual General Meeting
Published: 2022-03-01 (Crawled : 23:00) - globenewswire.com
CNHI | News | $12.36 -1.51% -0.08% 8M
|
Producer Manufacturing
|
| O: 0.65%
H: 3.65%
C: 2.94%
trial report
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer
Published: 2022-03-01 (Crawled : 22:00) - biospace.com/
KPTI | $1.375 25.0% 20.0% 3.1M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: 0.0%
trial cancer
Kennametal to Attend J.P. Morgan Industrials Conference
Published: 2022-03-01 (Crawled : 22:00) - prnewswire.com
KMT | News | $23.83 0.25% 0.0% 800K
|
Producer Manufacturing
|
| O: 1.69%
H: 3.97%
C: 2.77%
als trials trial conference
Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection
Published: 2022-03-01 (Crawled : 22:00) - globenewswire.com
FNCH | $2.5 -19.36% -24.0% 130K
|
Professional, Scientific, and T...
|
| O: -7.74%
H: 0.0%
C: 0.0%
cp101 trial therapeutics infection phase 3 infections
New Science 37® CNS Survey Confirms Growing Trend in Clinical Trials LandscapeWithin CNS indications, data suggest Agile Clinical Trials™ and decentralized approaches will become more prevalent in 2022 and beyond
Published: 2022-03-01 (Crawled : 19:00) - biospace.com/
SNCE | News | $5.75 0.26% 49K
|
|
| O: -1.35%
H: 2.99%
C: -8.46%
als trials trial clinical trials growing
New Analysis from Global Industry Analysts Reveals Steady Growth for Industrial X-Ray Inspection Systems, with the Market to Reach $816.3 Million Worldwide by 2026
Published: 2022-03-01 (Crawled : 17:00) - prnewswire.com
BKR | $32.03 -0.22% -0.22% 5.6M
|
Industrial Services
|
| O: 0.78%
H: 0.57%
C: -4.29%
als trial system growth
Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial
Published: 2022-03-01 (Crawled : 16:00) - biospace.com/
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
jardiance heart trial
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating RBB Bancorp (RBB) For Possible Securities Law Violations and Encourages Investors with Significant Losses to Contact Firm's Attorneys
Published: 2022-03-01 (Crawled : 15:00) - prnewswire.com
RBB 4 | $16.73 -0.24% -0.24% 29K
|
Finance
|
| O: -0.17%
H: 0.0%
C: -1.37%
trial
Visitt Signs Agreement with LXP Industrial Trust for Property Operations Digital Transformation
Published: 2022-03-01 (Crawled : 14:30) - prnewswire.com
LXP | $8.53 -3.29% 2.34% 2M
|
Finance
|
| O: -0.13%
H: 0.58%
C: 0.39%
trial trust
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia
Published: 2022-03-01 (Crawled : 13:30) - globenewswire.com
NTLA | $21.52 -1.33% -1.35% 1.1M
|
Health Technology
|
| O: -4.15%
H: 0.01%
C: -14.11%
ntla-5001 treatment myeloid leukemia leukemia 500 trial therapeutics intel phase 1 acute myeloid leukemia
BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada
Published: 2022-03-01 (Crawled : 13:30) - globenewswire.com
BCDA | $0.3642 -0.7% 32K
|
Health Technology
|
| O: -1.87%
H: 4.76%
C: 4.29%
health heart trial cel therapy cardiamp
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
Published: 2022-03-01 (Crawled : 13:30) - biospace.com/
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
phase 2 trial therapeutics therapy cancer pancreatic enroll
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
Published: 2022-03-01 (Crawled : 13:00) - biospace.com/
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
trial disease potential vaccine phase 3
New Science 37® CNS Survey Confirms Growing Trend in Clinical Trials Landscape
Published: 2022-03-01 (Crawled : 13:00) - globenewswire.com
SNCE | News | $5.75 0.26% 49K
|
|
| O: -1.35%
H: 2.99%
C: -8.46%
als trials trial clinical trials growing
CNH Industrial N.V. announces share buyback program – CEO purchases Company’s common shares
Published: 2022-03-01 (Crawled : 07:00) - globenewswire.com
CNHI | News | $12.36 -1.51% -0.08% 8M
|
Producer Manufacturing
|
| O: 2.18%
H: 0.77%
C: -2.94%
ces program ceo trial
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.